Skip to main content

Believing is Doing (1.21.2022)

Jan 20, 2022 11:45 pm

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. These reports are about better outcomes in Lupus; fewer Gout flares with T2T and the power of belief. 

  1. How Bad and How Far? CDC says to date, in the USA, there have been 6,715,937 COVID cases and 850,575 deaths from COVID-19. A total of 249,393,487 (75.1%) have recv at least one VAX dose, 209,312,770 (63%) fully VAX, 38.7% had a booster dose https://t.co/M9fYWL80ae
  2. JAMA reports that between Dec 2020 and July 2021, COVID-19 vaccination saved nearly 241,000 lives, prevented 1, 133, 617 hospitalizations and prevented more than 14 million COVID-19 cases (all in 1st 6 mos of the COVID vaccines) https://t.co/VIcwcPwbjn
  3. Lupus metanalysis of 41 studies, 17,270 pts shows that REMISSION was maintaned for 1 year in 42–88% of pts, and 5 yrs in 21–70%. Remission assoc w/ older age @dx, lower Dz activity, NO major organ involve. REM had less damage, better QOL https://t.co/1zPcITcYMo
  4. van Vollenhoven et al strategies onT2T in SLE 1) Choose a Target; treat, monitor, adjust 2) LLDAS & DORIS remission are good targets 3) T2T trials needed w/ current Rx & new biologics & sm molecules 4) LLDAS & DORIS as outcomes in clinical trials https://t.co/aTq398iaSD https://t.co/yWlp4vY7kh
  5. UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/FylgQ30Dva
  6. Using SKG mouse model of adjuvant induced SpA and enthesitis, neutrophils, and inducible IL-23, were shown to play an important role in early murine spondyloarthritis-related enthesitis. https://t.co/wlHXkNbvR7
  7. 192 early arthritis & 693 early arthralgia underwent the MTP-squeeze-test (MTPsqT) & MRI. Synovitis & intermetatarsal bursitis (IMB) were assoc w/ MTPsqT. In EA, MTPsqT +, 79% had synovitis or IMB: 12% synovitis, 15% IMB & 52% had both. https://t.co/Ojwb8KkmLu
  8. FDA has approved 2 JAK inhibitors for use in severe atopic dermatitis (eczema) - Abbvies upadacitinib (Rinvoq) and Pfizers abrocitinib (Cibinqo). https://t.co/WpCehmB7Vz https://t.co/qKoqV08Z86
  9. J Rheum reports rheums may not be adequately screening for HBV, HCV when using tofacitinib & tocilizumab, despite rec's from CDC, AASLD, PI (but not ACR) to do so. TCZ & TOFA had partial screening (45% & 50%) or no screening (26% & 26%) https://t.co/y28kSJ1JgA
  10. 791 knee OA pts studied for progression after steroid (GC) (n=629) vs hyaluronic (HA) injxn (n=162). Knee OA progression was similar between groups for JSN (RR 1.00) & K/L grade (1.03); but IA GC had slightly lower TKR (HR 0.75 [CI 0.51–1.09]) https://bit.ly/3qLapDe
  11. Herpes Zoster Vaccination in Immunocompromised Adults
  12. Does T2T Lead to Fewer Gout Flares?
  13. RheumNow Live: Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/c7oLLCllM8
  14. Believe – Hope goals and rules
Disclosures
The author has received compensation as an advisor or consultant on this subject

Rheumatologists’ Comments

philip molloy

| Jan 22, 2022 5:12 pm

i recommend you target 20 minutes as the maximum length for your weekly podcasts

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×